United Therapeutics (UTHR) Stock Price, News & Analysis

Company Overview

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets. Its medicines are used to help improve exercise capacity and delay disease progression in patients with PAH, a chronic condition involving high blood pressure in the arteries of the lungs.

In addition to its pharmaceutical business, the company is pursuing technologies intended to address the shortage of transplantable organs. Its research activities include the development of genetically engineered organs from pigs, lung regeneration and preservation, and three-dimensional bioprinting. United Therapeutics was founded in 1996 by Martine Rothblatt, who serves as chairperson and chief executive officer.

Key Stats

• Today's Range: $524.79 to $545.00
• 50-Day Range: $472.21 to $571.38
• 52-Week Range: $409.07 to $609.35
• Volume: 1.44 million shs
• Average Volume: 1.02 million shs
• Market Capitalization: $22.85 billion
• P/E Ratio: 19.06
• Dividend Yield: N/A
• Price Target: $627.31
• Consensus Rating: Moderate Buy

United Therapeutics Stock Analysis - MarketRank™

United Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 118th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

United Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

United Therapeutics has a consensus price target of $627.31, representing about 17.7% upside from its current price of $532.78.

Amount of Analyst Coverage

United Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 13.16%

Earnings Growth

Earnings for United Therapeutics are expected to grow by 13.16% in the coming year, from $26.21 to $29.66 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of United Therapeutics is 19.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of United Therapeutics is 19.06, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.65.

Price to Earnings Growth Ratio

United Therapeutics has a PEG Ratio of 2.73. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

United Therapeutics has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.14% of the float of United Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

United Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in United Therapeutics has recently increased by 35.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

United Therapeutics does not currently pay a dividend.

Dividend Growth

United Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.43

News Sentiment

United Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for United Therapeutics this week, compared to 11 articles on an average week.

Search Interest

11 people have searched for UTHR on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.

MarketBeat Follows

6 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $193,273,368.00 in company stock.

Percentage Held by Insiders

8.60% of the stock of United Therapeutics is held by insiders.

Percentage Held by Institutions

94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:UTHR
• CIK: 1082554
• Web: www.unither.com
• Phone: (301) 608-9292
• Fax: 301-608-9291
• Employees: 1,400
• Year Founded: 1996

Price Target and Rating

• Average Price Target for United Therapeutics: $627.31
• High Price Target: $735.00
• Low Price Target: $321.00
• Potential Upside/Downside: +17.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $27.95
• Trailing P/E Ratio: 19.06
• Forward P/E Ratio: 20.33
• P/E Growth: 2.73
• Net Income: $1.33 billion
• Net Margins: 41.56%
• Pretax Margin: 49.87%
• Return on Equity: 20.18%
• Return on Assets: 17.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.73
• Quick Ratio: 5.41

Sales & Book Value

• Annual Sales: $3.18 billion
• Price / Sales: 7.18
• Cash Flow: $32.25 per share
• Price / Cash Flow: 16.52
• Book Value: $164.81 per share
• Price / Book: 3.23

Miscellaneous

• Outstanding Shares: 42,890,000
• Free Float: 39,202,000
• Market Cap: $22.85 billion
• Optionable: Optionable
• Beta: 0.49